TradingKey

• FDA granted accelerated approval for Ultomiris to treat primary IgA nephropathy. • AstraZeneca reports annual revenue of $58.74B and net profit of $10.22B. • Analysts issued Buy ratings with an average price target of $210.32.

• Shopify shares dropped as investors engaged in profit-taking after a multi-week rally. • ATB Cormark downgraded Shopify stock from Outperform to Sector Perform. • Lower-margin Merchant Solutions and AI investments continue weighing on margin expansion.

• Arista Networks faced downward pressure from valuation recalibration and profit-taking. • Executive stock transactions revealed extensive insider share sales under trading plans. • Analysts lowered price targets amid component shortages and valuation concerns.

• Citizens JMP lowered Alphabet's price target amid rising artificial intelligence search competition. • Aggressive capital expenditures for artificial intelligence infrastructure constrained near-term free cash flow. • Alphabet's latest annual revenue reached $402.84B with net profit at $132.17B.

On October 22 Eastern Time, Moderna (MRNA) shares tumbled as much as 25% intraday. As of press time, the stock remained down 24.24% at $186.23. Reportedly, full Phase 3 data for the melanoma vaccine jointly developed by the company and Merck (MRK) is set to be released soon, while rumors circulated in the market that the trial results were leaked in advance, though this has not been officially confirmed.

• Arm shares dropped amid sector-wide AI selloffs and high valuation pressures. • Qualcomm court disputes created uncertainty regarding high-margin licensing royalty revenues. • Institutional investors increased defensive options ahead of the upcoming quarterly earnings.

• Oracle shares dropped due to heavy AI capital expenditures and elevated leverage. • High cash burn and debt burdens overshadow massive cloud infrastructure revenue backlogs. • Technical indicators show a MACD sell signal and oversold Williams %R conditions.

• Merck shares faced downward pressure from profit-taking and prominent analyst downgrades. • Investors expressed concern over upcoming quarterly earnings and Keytruda patent expiration. • Annual revenue reached $65.01B with a net profit of $18.25B.

• GE Vernova fell due to sector-wide pullback in AI and power infrastructure. • Persistent profitability drags within the Wind segment weighed on investor sentiment. • The MACD value of negative thirty indicates a current sell signal.

On October 22, Eastern Time, amid a sell-off in AI-related stocks, Berkshire Hathaway (BRK.A) (BRK.B) reached a new all-time high once again. As of press time, the company's shares were up 1.53% at $823,750. Yields on the company's massive cash reserves under elevated short-term interest rates, combined with the strong performance of major holdings such as Apple and Coca-Cola, may be key factors driving the stock price higher.

• Lam Research shares fell despite beating fiscal first-quarter revenue and earnings expectations. • December quarter guidance missed elevated buy-side expectations amid supply chain constraints. • China revenue is expected to decline significantly in subsequent quarters.

• Dell shares pulled back following Wall Street downgrades due to elevated valuations. • Rising memory component costs and supply chain frictions raise margin compression concerns. • The MACD value indicates a sell signal amid extremely bearish market sentiment.

• Johnson and Johnson shares advanced following positive clinical trial data in electrophysiology. • Management raised full-year sales and adjusted earnings guidance amid solid third-quarter performance. • Institutional capital rotated into the healthcare leader, supported by strong dividend history.

• Netflix stock rebounded positively after investors capitalized on a sharp post-earnings decline. • Third-quarter diluted earnings per share and operating margins exceeded Wall Street consensus estimates. • Management executed a record quarterly share repurchase of nearly five billion dollars.

• Palo Alto Networks shares advanced amid supportive technology market sentiment and enterprise demand. • The platformization strategy drives Next-Generation Security annual recurring revenue and long-term expansion. • Annual revenue reached $11.48B, with analysts maintaining an average price target of $400.15.

On October 22, Eastern Time, US stocks tumbled, with the Nasdaq Composite Index falling more than 2%. The Philadelphia Semiconductor Index dropped over 6%, reaching its lowest level since July 29. Meta's disclosure of a massive spending commitment reportedly further heightened market concerns over the scale of AI investments and financing pressures. Meanwhile, reports indicated that the US and Israel plan to launch another military strike against Iran after the US midterm elections.

• Broadcom faced volatility due to AI sector headwinds and high capital costs. • Institutional investors trimmed holdings to manage concentration risks following a multi-year rally. • Analysts maintain strong fundamental support citing AI leadership and robust cash flow.

• Nvidia shares dropped due to broader tech sector risk-off sentiment and inflation concerns. • Semiconductor supply chain earnings failed to exceed exceptionally high market valuation expectations. • Nvidia reports $215.94B annual revenue, ranking first in the technology equipment industry.

• Analysts raised Eli Lilly targets ahead of third-quarter earnings. • Strong demand for Mounjaro and Zepbound drove momentum. • Capital investments expanded manufacturing facilities globally.

• Micron faced downward pressure from broad semiconductor sell-offs and rising Treasury yields. • Labor negotiations in Taiwan created localized operational headwinds and supply chain concerns. • Investor sentiment was tempered by debates over AI capital expenditure pacing.